Peanut Allergy
Pipeline by Development Stage
Drug Modality Breakdown
Competitive Landscape
11 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 24 trials with date data
Clinical Trials (26)
Total enrollment: 5,023 patients across 26 trials
Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children
Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age
Follow-up of the PEPITES Study to Evaluate Long-term Efficacy and Safety of Viaskin Peanut in Children
Safety Study of Viaskin Peanut to Treat Peanut Allergy
Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy
A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy
The Peanut Oral Immunotherapy Study: Safety, Efficacy and Discovery
Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children
Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy
Epicutaneous Immunotherapy in Peanut Allergy in Children
Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy
VE416 for Treatment of Food Allergy
Tolerance Following Peanut Oral Immunotherapy
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IGNX001
CNP-201 in Subjects With Peanut Allergy
Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-201 in Subjects Ages 16-35 With Peanut Allergy
A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine
A Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut Allergic Subjects
A Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine
HAL-MPE1 Safety and Tolerability Study
HAL-MPE1 First-in-human
Safety of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy
Expanded Access Protocol of Viaskin® Peanut (DBV712) in Peanut-allergic Children
Viaskin® Peanut (DBV712) Expanded Access Protocol
Follow up of LEAP Participants and Their Families
High Threshold Peanut Challenge Study
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.